Adoptive cell therapy in colorectal cancer: Advances in chimeric antigen receptor T cells

Table 2 Chimeric antigen receptor-T drugs approved by the Food and Drug Administration and China

Drug name	Indication	Approval date	Developer	Approved countries	Target
Kymriah (tisagenlecleucel)	B-cell acute lymphoblastic leukemia in children and young adults	August 30, 2017 (FDA)	Novartis	United States, European, Canada, Australia, China	CD19
		December 2018 (China)
Yescarta (axicabtagene ciloleucel)	Large B-cell lymphoma in adults	October 18, 2017 (FDA)	Kite Pharma (Gilead)	United States, European, Canada, China	CD19
		February 2020 (China)
Tecartus (brexucabtagene autoleucel)	Relapsed or refractory mantle cell lymphoma	July 24, 2020 (FDA)	Kite Pharma (Gilead)	United States, European, etc.	CD19
Breyanzi (lisocabtagene maraleucel)	Large B-cell lymphoma in adults	February 5, 2021 (FDA)	Bristol Myers Squibb	United States, European, Canada, etc.	CD19
Abecma (idecabtagene vicleucel)	Multiple myeloma	March 26, 2021 (FDA)	Bristol Myers Squibb/Bluebird Bio	United States, European, China	BCMA
		February 2022 (China)
Carvykti (ciltacabtagene autoleucel)	Multiple myeloma	February 28, 2022 (FDA)	Johnson and Johnson/Legend Biotech	United States, European, China	BCMA
		November 2022 (China)
Kymriah (tisagenlecleucel)	Large B-cell lymphoma in adults	May 2021 (China)	Novartis	China	CD19
Blinatumomab (blincyto)	B-cell acute lymphoblastic leukemia	October 2019 (China)	Amgen	China	CD19

CD: Cluster of differentiation; BCMA: B-cell maturation antigen; FDA: Food and Drug Administration.